Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir
Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 5,666,392 | $628,232,881 | +4% | 0.84% |
| 2. | Citadel Investment Group Ken Griffin | 5,470,545 | $606,519,324 | +2% | 0.11% |
| 3. | Holocene Advisors Brandon Haley | 4,226,971 | $468,644,275 | +84% | 1.14% |
| 4. | AQR Capital Management Cliff Asness | 2,470,838 | $272,212,219 | +33% | 0.23% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,950,813 | $216,286,637 | +153% | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $114.09 | 8,345 | $952,076.88 | 605,725 | 2025-07-28 | Filing | |
| $113.17 | 1,655 | $187,292.71 | 614,070 | 2025-07-28 | Filing | |
| $111.03 | 3,000 | $333,090.00 | 117,168 | 2025-07-15 | Filing | |
| $111.03 | 2,500 | $277,575.00 | 162,610 | 2025-07-15 | Filing | |
| $109.74 | 5,000 | $548,700.00 | 8,920 | 2025-07-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 119,364,226 | $13,233,911,737 | 0.21% | |
| 2. | 114,879,922 | $12,736,736,912 | 0.24% | |
| 3. | 59,955,377 | $6,647,252,652 | 0.37% | |
| 4. | 59,188,160 | $6,562,191,299 | 0.25% | |
| 5. | 46,303,299 | $5,133,588,254 | 0.75% |
News See All
Gilead Sciences' Twice-Yearly HIV Prevention Drug Recommended for Approval by European Medicines Agency
Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds.
11 Best GLP-1 and Weight Loss Stocks to Invest in
GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite.
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish
Gilead Sciences jumped to a new all-time high on Friday as investors cheered its impressive earnings performance in the second quarter of the year, alongside bullish ratings and price targets from 10 ...
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Second Quarter 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
12 Most Undervalued Quality Stocks to Buy According to Hedge Funds
On July 31, Nadia Lovell, UBS senior equity strategist, joined 'The Exchange' on CNBC to discuss why she believes this rally has staying power, and to suggest that investors stay up in quality on secular...
Morgan Stanley Remains Bullish on Gilead Sciences (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst Terence Flynn maintained a bullish stance on Gilead Sciences, Inc.
11 Cheap Pharmaceutical Stocks to Buy Now
The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the steps they should take to decrease the prices of US prescription drugs to “most...
Citi Maintains a Buy Rating on Gilead Sciences (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now.
TD Cowen Remains Bullish on Gilead Sciences (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences, Inc.
Billionaire Hedge Funds
